# A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma

> **NCT05390528** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Tumors
- Lymphoma
- Metastatic Tumors

## Interventions

- **DRUG:** HLX301

## Key facts

- **NCT ID:** NCT05390528
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-20
- **Primary completion:** 2023-09-01
- **Final completion:** 2024-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05390528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05390528, "A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05390528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*